Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01359878
Other study ID # 2009-017736-41
Secondary ID 2009-017736-4110
Status Completed
Phase Phase 2/Phase 3
First received May 20, 2011
Last updated September 19, 2013
Start date May 2011
Est. completion date July 2013

Study information

Verified date September 2013
Source Copenhagen University Hospital at Herlev
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Dataprotection AgencyDenmark: Danish Medicines AgencyDenmark: The Danish National Committee on Biomedical Research EthicsDenmark: The Regional Committee on Biomedical Research Ethics
Study type Interventional

Clinical Trial Summary

Severe maternal bleeding is a serious complication of birth and causes 125.000 deaths worldwide each year. The investigators aim to investigate if early treatment with fibrinogen concentrate versus saline can reduce the incidence of blood transfusion in women with postpartum haemorrhage.

A low level of fibrinogen has been associated with increased blood loss and transfusion requirements in different clinical settings including obstetrical bleeding. Early up-front treatment with fibrinogen may reduce incidence of transfusion by securing optimal haemostatic capacity in women with postpartum haemorrhage.

The investigators plan to enrol 245 patients on four hospitals in the Capital Region of Denmark during a two year period.

As safety measure the investigators plan to use TEG®/Functional Fibrinogen/Rapid-TEG as haemostatic monitoring of all participants during the trial: Baseline test is taken at inclusion before administration of fibrinogen concentrate/placebo. Further tests are taken immediately after intervention, 4 hours and 24 hours after. Baseline test is blinded to the providers of treatment - the rest is clinically available.


Description:

Experimental design Design: We plan to conduct a randomised double-blinded clinically controlled trial: The participants are assigned to either 1) placebo (100 ml of isotonic saline) i.v. or 2) the intervention drug: 2 g of fibrinogen concentrate (Haemocomplettan, CSL Behring) i.v. We intend to use a fixed dose for all patients randomized to the intervention group without prior measurement of the fibrinogen level. This strategy is primarily based on the clinical urgency since the treatment is required to be administered as early as possible.

Materials and duration of study Patients will be included during a two year period at the four largest hospitals in the Capital Region: Rigshospitalet, Hvidovre, Hillerød and Herlev if they fulfil the following eligibility criteria Plan of trial execution In order to secure the ethical aspect "Time for reflection" we will provide all pregnant women who appear in the centres during the trial period with written information on the trial during their midwife evaluation. Only 1,75% of these women are estimated to meet the inclusion criteria postpartum.

Intensive haemostatic monitoring Haemostatic blood samples including thrombelastography (TEG®), functional fibrinogen-assay for TEG®, Rapid-TEG, fibrinogen-level, d-Dimer, INR (international normalized ratio), platelet count and Antithrombin III will be drawn 15 minutes after the intervention is given, 4 hours and 24 hours later. The samples taken after the intervention are fully available for evaluation by the clinicians responsible for the patient. The patient will be observed with blood pressure, pulseoximetry, ECG and possible side effects or re-bleeding will be evaluated.

Follow up The patients will remain hospitalized for a minimum of 24 hours. We will contact all participants by phone six weeks after the intervention. Upon discharge from the hospital, all included patients receive information-material addressing possible late side effects and a contact number.


Recruitment information / eligibility

Status Completed
Enrollment 249
Est. completion date July 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Informed consent from participant.

2. Women who develop PPH defined as bleeding from uterus and/or the birth canal within 24 hours postpartum.

3. Age = 18 years.

4. If vaginal birth: indication of one of the following procedures at the operation theatre with anaesthetic assistance: a) Estimated blood loss = 500 ml and indication of manual removal of placenta or b) Indication of manual exploration of the uterus due to continuous bleeding after the birth of placenta.

5. If birth by Caesarean section: A perioperative blood loss = 1000 ml.

Exclusion Criteria:

1. Patients with known inherited deficiencies of coagulation.

2. Patients in anti-thrombotic treatment prepartum due to increased risk of thrombosis.

3. Patients with a pre-pregnancy weight <45 kg.

4. Patients who refuse to receive blood transfusion.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Drug:
Fibrinogen Concentrate
2 gram intra venous
Isotonic Saline
Isotonic saline in equivalent volume - 100 ml

Locations

Country Name City State
Denmark Juliane Marie Centre, Rigshospitalet Copenhagen Capital Region
Denmark University Hospital of Herlev Herlev Capital Region
Denmark University Hospital of Hilleroed Hilleroed Capital Region
Denmark University Hospital of Hvidovre Hvidovre Capital Region

Sponsors (14)

Lead Sponsor Collaborator
Copenhagen University Hospital at Herlev Aase and Ejnar Danielsens Foundation, Blood Bank of the Danish capital region, Copenhagen University Hospital, Hvidovre, Danish Council for Independent Research, Fonden til Lægevidenskabens Fremme, Haemonetics Corporation, Hans og Nora Buchards Fond, Herlev Hospital, Hillerod Hospital, Denmark, Laerdal Acute Foundation, Rigshospitalet, Denmark, The fund of 17-12-1981, Unit for monitoring of Good Clinical Practice Copenhagen University

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidense of transfusion with allogenic blood products During hospital stay or until 6 weeks postintervention No
Secondary Severe Postpartum Haemorrhage (PPH) Development of "Severe PPH" defined as: "Decrease of haemoglobin (Hb) of > 2,5 mmol/L, transfusion of at least 4 Red Blood Cell (RBC) units, haemostatic intervention (angiographic embolization, surgical arterial ligation or hysterectomy) or death. During hospital stay or until 6 weeks postintervention No
Secondary Estimated blood loss During hospital stay During hospital stay or until 6 weeks postintervention No
Secondary Total amount of blood transfused During hospital stay During hospital stay or until 6 weeks postintervention No
Secondary The development of re-bleeding Defined as bleeding reoccuring after primary haemostasis, and requiring surgical procedures or intervention Untill follow-up 6 weeks postintervention Yes
Secondary Hemoglobin level below 3,6 mmol/L During hospital stay or until 6 weeks postintervention No
Secondary Side-effects including thromboembolic complications Safety measures/ Potential known side effects such as: Fever, headache, nausea, vomiting, allergic reactions, anaphylaxis and thrombo-embolic complications (deep venous thrombosis, acute myocardial infarct and lung embolus. All suspected unexpected serious adverse reactions will also be reported in accordance with the Good Clinical Practice (GCP) and the Danish Medicines Agency guidelines. Untill 6 weeks postintervention Yes
See also
  Status Clinical Trial Phase
Completed NCT02509351 - Could Pre-operative Rectal Misoprostol Reduce Intra-operative Blood Loss During Ceserean Section? Phase 2/Phase 3
Completed NCT01931423 - The Influence of Placental Drainage of Management of the Third Stage of Labor:a Randomized Controlled Study N/A
Completed NCT00499005 - Carbetocin Versus Syntometrine for the Third Stage of Labour Phase 4
Completed NCT01485562 - Treatment of Postpartum Haemorrhage (PPH) Using Misoprostol in Home Births N/A
Completed NCT00872469 - World Maternal Antifibrinolytic Trial Phase 3
Completed NCT02704780 - Two Different Regimens of Misoprostol in Retained Placenta Phase 2
Not yet recruiting NCT02396303 - Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage Phase 0
Completed NCT01895218 - Treatment of Women After Postpartum Haemorrhage Phase 3
Completed NCT01931410 - The Effect of Rectal and Sublingual Misoprostol Administration in Postpartum or Intrapartum Haemorrhage at Elective Caesarean Delivery: a Randomized Controlled Trial Phase 4
Recruiting NCT02187874 - Timing of Umbilical Cord Occlusion in Premature Babies( <33 w). Delayed vs Early. N/A
Withdrawn NCT01910675 - PCC and Fibrinogen Compared With FFP in PPH Phase 4
Completed NCT02562300 - Uterotonics Using to Reduce Bleeding at Cesarean Section Phase 2
Completed NCT01044082 - Prevention of Post-partum Haemorrhage N/A
Completed NCT01116050 - Intrarectal Misoprostol in Postpartum Haemorrhage Phase 3
Completed NCT02149472 - Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage
Recruiting NCT02492087 - Topical Tranexamic Acid in Caesarean Section Phase 3
Completed NCT02468310 - Evaluating the Effects of SMS Text Messaging Support System Among Frontline Health Workers in Ghana N/A
Recruiting NCT02136719 - Bimanual Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery N/A